Search

Your search keyword '"Laskin, J."' showing total 43 results

Search Constraints

Start Over You searched for: Author "Laskin, J." Remove constraint Author: "Laskin, J." Database Academic Search Index Remove constraint Database: Academic Search Index
43 results on '"Laskin, J."'

Search Results

1. NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents.

2. Integration of a nurse navigator into the triage process for patients with non-small-cell lung cancer: creating systematic improvements in patient care.

3. Adjuvant Chemotherapy in Resected Stage II Non-small Cell Lung Cancer: Evaluating the Impact of Dose Intensity and Time to Treatment.

4. Mandibular tumorous condition in a 9-week-old child.

5. Ryanodine-Sensitive Calcium Flux Regulates Motility of Arbacia punctulata Sperm.

6. Immune Activation following Irbesartan Treatment in a Colorectal Cancer Patient: A Case Study.

9. 87P Application of tissue and liquid-based next generation sequencing (NGS) for comprehensive genomic profiling: Evaluating the clinical value of ctDNA technology in treatment decision making.

11. Evaluation of a ‘Watch and Wait’ Approach for Chemotherapy in Patients with Newly Diagnosed Advanced Non-small Cell Lung Cancer from a Diverse Community Population.

13. LBA65 KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.

14. Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.

15. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.

16. Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer.

17. Self-consistent determination of fullerene binding energies BE (C+n–C2), n=58· · ·44.

21. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.

22. Personalized oncogenomics in the management of gastrointestinal carcinomas--early experiences from a pilot study.

23. Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer.

26. Histologic classification of non-small-cell lung cancer over time: reducing the rates of not-otherwise-specified.

27. Histologic classification of non-small-cell lung cancer over time: reducing the rates of not-otherwise-specified.

28. A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.

29. Beta-catenin expression is prognostic of improved non-small cell lung cancer survival.

32. Effects of testing context on ball skill performance in 5-year-old children with and without developmental delay.

34. 475OOverall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI).

35. 63ONRG1-fusion-driven solid tumours: A case series indicating the therapeutic potential of afatinib.

40. 2060 - Afatinib vs gefitinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7).

Catalog

Books, media, physical & digital resources